TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04392128
Drug: Azithromycin 250 MG Oral Capsule
Normalized name: azithromycin 250 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin is amacrolide antibiotic.
Study: NCT04392128
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Hydroxychloroquine Sulfate 200 MG \[Plaquenil\].
Study: NCT04392128
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Azithromycin capsules.
Study: NCT01980407
Drug: S-1, leucovorin, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
Study: NCT01337674
Drug: MK-4618
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
Study: NCT01337674
Drug: Placebo for MK-4618
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
Study: NCT00733174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02115659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
Study: NCT02044627
Drug: [14C-ETC-1002]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00222365
Drug: Bryonia alba, 5 CH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00222365
Drug: Hypericum perforatum, 5 CH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00222365
Drug: Ruta graveolens, 3 DH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00737204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
Study: NCT01712009
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
Study: NCT00503022
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03350334
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration
Study: NCT02240108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study: NCT03041779
Drug: Paracetamol 500Mg Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01991275
Drug: The intravenous patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Study: NCT03530631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered placebo
Study: NCT00827515
Drug: PH797804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
Study: NCT00827515
Drug: PH797804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
Study: NCT03308591
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platin based chemotherapy
Study: NCT01677884
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
Study: NCT03257852
Drug: ASP5094
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously administration
Study: NCT03257852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously administration
Study: NCT04447352
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes
Study: NCT03479918
Drug: R-DA-EPOCH-21
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study: NCT03479918
Drug: R-BL-M-04
Normalized name: M/R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study: NCT03479918
Drug: R-DA-EPOCH-21 + auto-SCT
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study: NCT03479918
Drug: R-BL-M-04 + auto-SCT
Normalized name: M/R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study: NCT02284607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MHAA4549A administration
Study: NCT01314066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
Study: NCT00281632
Drug: GW786034
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg GW786034 administered orally on a daily basis.
Study: NCT01542437
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug.
Study: NCT04012905
Drug: Corticosteroids for Systemic Use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month
Study: NCT04064242
Drug: CMK389
Approvals — FDA: no, EMA: no, PMDA: no
Description: single i.v. dose every 4 weeks
Study: NCT04064242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single i.v. dose every 4 weeks
Study: NCT00827515
Drug: PH797804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
Study: NCT00827515
Drug: PH797804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
Study: NCT04577326
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
Study: NCT01491815
Drug: Non-biological DMARD's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
Study: NCT03144271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo will be administered subcutaneously (s.c. under the skin)
Study: NCT03644485
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
Study: NCT03644485
Drug: Mycophenolic acid drugs
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
Study: NCT05488990
Drug: AKVANO vehicle formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel lipid based formulation (AKVANO) vehicle 1
Study: NCT03644485
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
Study: NCT01321554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
Study: NCT05488990
Drug: AKVANO vehicle formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel lipid based formulation (AKVANO) vehicle 2
Study: NCT00048932
Drug: Double-blind Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
Study: NCT00502684
Drug: Propranolol, etodolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
Study: NCT01487460
Drug: TAP311
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01986881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
Study: NCT00672581
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg, Oral tablet, single dose
Study: NCT01323595
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg PO BID x 6 days
Study: NCT02222480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00791661
Drug: MK-1006
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
Study: NCT00791661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK-1006 in a single oral dose
Study: NCT04229602
Drug: EFEXOR® XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
Study: NCT03614078
Drug: PRCL-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT03614078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01308606
Drug: TMC435 HPMC capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intake of one 150-mg capsule without food
Study: NCT00002801
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04083716
Drug: ABI-H2158 Reference Formulation
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H2158 tablets Reference Formulation
Study: NCT04083716
Drug: ABI-H2158 Test Formulation
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-H2158 tablets Test Formulation
Study: NCT00135018
Drug: celecoxib and chemotherapy
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03830320
Drug: [64Cu]FBP8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Copper-64 radiopeptide to detect thrombosis
Study: NCT02338999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01603108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
Study: NCT02860949
Drug: 0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02004886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching MK-0893
Study: NCT02004886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching metformin
Study: NCT02247596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill 1g tds for 2 weeks
Study: NCT04190628
Drug: ABM-1310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
Study: NCT02318043
Drug: inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
Study: NCT02638506
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
Study: NCT03737110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC injections once weekly
Study: NCT05474950
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: minocycline capsule (100mg) per day orally
Study: NCT03312153
Drug: Neem
Normalized name: neem
Approvals — FDA: no, EMA: no, PMDA: no
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial
Study: NCT00662857
Drug: Technosphere® Insulin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: TI Inhalation Powder, two 15 U cartridges
Study: NCT00662857
Drug: Technosphere Insulin® Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: TI Inhalation Powder, one 30 U cartridge
Study: NCT01558310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
Study: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP-001, dose-level 1, s.c., single-dose
Study: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP-001, dose-level 2, s.c., single-dose
Study: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP-001, dose-level 3, s.c., single-dose
Study: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP-001, dose-level 4, s.c., single-dose
Study: NCT01010425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, s.c., single-dose
Study: NCT02275780
Drug: TRUVADA™ or EPZICOM™/KIVEXA™
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
Study: NCT00679289
Drug: HDI
Normalized name: Fanhdi
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression
Study: NCT03460457
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics/Dynamics Study
Study: NCT00994851
Drug: SENNA+CASSIA
Normalized name: Padang cassia oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
Study: NCT00994851
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
Study: NCT04143594
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered without regard to food
Study: NCT04143594
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered without regard to food
Study: NCT01208506
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of NNC0114-0000-0005 placebo.
Study: NCT03706885
Drug: Sustiva Pill
Normalized name: Sustiva Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Study: NCT00093587
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00154232
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02323646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Study: NCT01154348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, taken once daily with morning meal
Study: NCT00687570
Drug: Laxabon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxabon® 4 litres starting the day before surgery
Study: NCT00703092
Drug: Fiber-Stat
Normalized name: Fiber-Stat with FOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid fiber supplement, 2 tablespoons twice daily.
Study: NCT04325425
Drug: FOLFOXIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
Study: NCT02255305
Drug: Antimicrobials
Normalized name: ANTIMICROBIALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the control group will receive antimicrobials targeting C. difficile.
Study: NCT01544998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
Study: NCT03107078
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Glucocorticoids (GCs)
Study: NCT02231138
Drug: Abelmoschus manihot (AM)
Normalized name: Abelmoschus manihot whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
Study: NCT00514683
Drug: intermediate dose BIBF 1120 twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intermediate dose BIBF 1120 twice daily
Study: NCT00514683
Drug: high dose BIBF 1120 twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose BIBF 1120 twice daily
Study: NCT00514683
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04546399
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT04546399
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04546399
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, PO, and IV
Study: NCT02417103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04684628
Drug: 68Ga-PSMA PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
Study: NCT03395184
Drug: PF-06651600 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
Study: NCT00810836
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00810836
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03207464
Drug: [C-11]Methylreboxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.
Study: NCT00810836
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: NCT00790452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet daily by mouth